Childhood obesity guidance, breast cancer maintenance treatment and AI-ready biology.
Public health
WHO releases first global guidelines on childhood and adolescent obesity
WHO’s new guidelines put structured nutrition, physical activity and behavioural support at the centre of obesity care. They do not recommend weight-loss medicines or surgery for children aged 0–9; approved medicines may be considered for adolescents when supervised lifestyle programmes have not achieved the desired results.
Why it matters: Provides an important reference for paediatric healthcare teams and responsible communication about obesity treatments.
FDA approves tucatinib combination for HER2-positive breast cancer maintenance
The FDA approved tucatinib with trastuzumab and pertuzumab for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. In HER2CLIMB-05, median progression-free survival was 24.9 months with tucatinib versus 16.3 months with placebo, both alongside the antibody treatments; overall survival results were not yet mature.
Why it matters: Expands the US-approved maintenance options and brings new evidence for oncology and pharma teams to assess.
Biohub initiative reaches $1.8 billion to build AI-ready biology data
Reuters reports that government and technology-sector commitments bring Biohub’s Virtual Biology Initiative to $1.8 billion. The project aims to generate cellular datasets for predictive AI models, with eventual public access; some commercially funded data will have an initial exclusive-access period.
Why it matters: Highlights investment in the data infrastructure behind AI drug discovery, although faster development remains a goal rather than a demonstrated outcome.
Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.